Degos disease: A C5b-9/interferon-a-mediated endotheliopathy syndrome

American Journal of Clinical Pathology

Volumn 135, Issue 4, 2011, Pages 599-610

  Magro, Cynthia M ^a   Poe, Jonathan C ^b   Kim, Connie ^c   Shapiro, Lee ^d   Nuovo, Gerard ^e   Crow, Mary K ^f   Crow, Yanick J ^g  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d ALBANY MEDICAL COLLEGE   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f HOSPITAL FOR SPECIAL SURGERY   (United States)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Angiopathy; Autoimmune disease; Central nervous system; Degos disease; Gastrointestinal tract; Skin

Indexed keywords

ALPHA INTERFERON; COMPLEMENT COMPONENT C5B;

ADULT; ARTERY DISEASE; ARTICLE; BRAIN DISEASE; CHILD; CLINICAL ARTICLE; ENDOTHELIUM CELL; FEMALE; HEART DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MALIGNANT ATROPHIC PAPULOSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SKIN BIOPSY; SKIN DEFECT; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADULT; AUTOIMMUNE DISEASES; BLOOD VESSELS; BRAIN; CHILD, PRESCHOOL; COMPLEMENT MEMBRANE ATTACK COMPLEX; ENDOTHELIUM, VASCULAR; FATAL OUTCOME; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GASTROINTESTINAL TRACT; HUMANS; INTERFERON-ALPHA; MALE; MALIGNANT ATROPHIC PAPULOSIS; MIDDLE AGED; SKIN; THROMBOTIC MICROANGIOPATHIES;

EID: 79954579299     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP66QIMFARLZKI     Document Type: Article

References (53)

1. Beljaards RC, Starink TM, Meuwissen SG. 2 families with malignant atrophic papulosis (Degos disease) [in Dutch]. Ned Tijdschr Geneeskd. 1988;132:269-271. (Pubitemid 18036830)
2. Durie BG, Stroud JD, Kahn JA. Progressive systemic sclerosis with malignant atrophic papulosis. Arch Dermatol. 1969;100:575-581.
3. Fernandez-Flores A, Manjon JA, Mencia J. Diabetes mellitus and Degos disease [published correction appears in Bratisl Lek Listy. 2008;109:533]. Bratisl Lek Listy. 2008;109:414-417.
4. Snow JL, Muller SA. Degos syndrome: Malignant atrophic papulosis. Semin Dermatol. 1995;14:99-105.
5. Doutre MS, Beylot C, Bioulac P, et al. Skin lesions resembling malignant atrophic papulosis in lupus erythematosus. Dermatologica. 1987;175:45-46.
6. Notash AY, Mazoochy H, Mirshams M, et al. Lethal systemic Degos disease with prominent cardio-pulmonary involvement. Saudi Med J. 2008;29:133-137.
7. High WA, Aranda J, Patel SB, et al. Is Degos' disease a clinical and histological end point rather than a specific disease? J Am Acad Dermatol. 2004;50:895-899. (Pubitemid 38685769)
8. Guhl G, Diaz-Ley B, Delgado Y, et al. Wegener's granulomatosis: A new entity in the growing differential diagnosis of Degos' disease. Clin Exp Dermatol. 2009;34:e1-e3. doi:10.1111/j.1365-2230.2008.02953.x.
9. Tsao H, Busam K, Barnhill RL, et al. Lesions resembling malignant atrophic papulosis in a patient with dermatomyositis. J Am Acad Dermatol. 1997;36:317-319. (Pubitemid 27078895)
10. Hohwy T, Jensen MG, Tøttrup A, et al. A fatal case of malignant atrophic papulosis (Degos' disease) in a man with factor V Leiden mutation and lupus anticoagulant. Acta Derm Venereol. 2006;86:245-247. (Pubitemid 43875213)
11. Katz SK, Mudd LJ, Roenigk HH Jr. Malignant atrophic papulosis (Degos' disease) involving three generations of a family. J Am Acad Dermatol. 1997;37(3 pt 1):480-484. (Pubitemid 27430648)
12. Yeo TH, Vassallo G, Judge M, et al. Infantile neurological Degos disease [published online ahead of print July 24, 2010]. Eur J Paediatr Neurol. doi:10.1016/j.ejpn.2010.06.003.
13. Magro CM, Iwenofu OH, Kerns MJ, et al. Fulminant and accelerated presentation of dermatomyositis in two previously healthy young adult males: A potential role for endotheliotropic viral infection. J Cutan Pathol. 2009;36:853-858.
14. Crowson AN, Magro CM, Usmani A, et al. Immunoglobulin A-associated lymphocytic vasculopathy: A clinicopathologic study of eight patients. J Cutan Pathol. 2002;29:596-601. (Pubitemid 35454444)
15. Magro CM, Segal JP, Crowson AN, et al. The phenotypic profile of dermatomyositis and lupus erythematosus: A comparative analysis [published online ahead of print November 4, 2009]. J Cutan Pathol. 2010;37:659-671.
16. Magro CM, Crowson AN. The immunofluorescent profile of dermatomyositis: A comparative study with lupus erythematosus.. J Cutan Pathol. 1997;24:543-552. (Pubitemid 27487431)
17. Crowson AN, Magro CM. The role of microvascular injury in the pathogenesis of cutaneous lesions of dermatomyositis. Hum Pathol. 1996;27:15-19. (Pubitemid 26015576)
18. Kirou KA, Lee C, George S, et al. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus. Arthritis Rheum. 2004;50:3958-3967. (Pubitemid 39643944)
19. Magro CM, Nuovo G, Ferri C, et al. Parvoviral infection of endothelial cells and stromal fibroblasts: A possible pathogenetic role in scleroderma. J Cutan Pathol. 2004;31:43-50. (Pubitemid 38130275)
20. Assier H, Chosidow O, Piette JC, et al. Absence of antiphospholipid and anti-endothelial cell antibodies in malignant atrophic papulosis: A study of 15 cases. J Am Acad Dermatol. 1995;33(5 pt 1):831-833.
21. Shingu M, Hurd ER. Sera from patients with systemic lupus erythematosus reactive with human endothelial cells. J Rheumatol. 1981;8:581-586. (Pubitemid 12244879)
22. del Papa N, Meroni PL, Barcellini W, et al. Antibodies to endothelial cells in primary vasculitides mediate in vitro endothelial cytotoxicity in the presence of normal peripheral blood mononuclear cells. Clin Immunol Immunopathol. 1992;63:267-274.
23. Kaneko K, Savage CO, Pottinger BE, et al. Antiendothelial cell antibodies can be cytotoxic to endothelial cells without cytokine pre-stimulation and correlate with ELISA antibody measurement in Kawasaki disease. Clin Exp Immunol. 1994;98:264-269. (Pubitemid 24336824)
24. Negi VS, Tripathy NK, Misra R, et al. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol. 1998;25:462-466.
25. Wusirika R, Ferri C, Marin M, et al. The assessment of anti-endothelial cell antibodies in scleroderma-associated pulmonary fibrosis: A study of indirect immunofluorescent and Western blot analysis in 49 patients with scleroderma. Am J Clin Pathol. 2003;120:596-606. (Pubitemid 37186054)
26. Kolb WP, Muller-Eberhard HJ. Neoantigens of the membrane attack complex of human complement. Proc Natl Acad Sci U S A. 1975;72:1687-1689.
27. Young JD, Cohn ZA, Podack ER. The ninth component of complement and the pore-forming protein (perforin 1) from cytotoxic T cells: Structural, immunological, and functional similarities. Science. 1986;233:184-190. (Pubitemid 16008112)
28. Hillmen P, Hall C, Marsh JC, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350:552-559. (Pubitemid 38160785)
29. Hill A, Hillmen P, Richards SJ, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:2559-2565. (Pubitemid 41510834)
30. Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant. 2009;9:231-235.
31. Mache CJ, Acham-Roschitz B, Frémeaux-Bacchi V, et al. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2009;4:1312-1316.
32. Kaplan M. Eculizumab (Alexion). Curr Opin Investig Drugs. 2002;3:1017-1023.
33. Haller O, Gao S, von der Malsburg A, et al. Dynamin-like MXA GTPase: Structural insights into oligomerization and implications for antiviral activity [published online ahead of print June 10, 2010]. J Biol Chem. 2010;285:28419-28424.
34. Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferonalpha/ beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005;57:664-678. (Pubitemid 40628855)
35. Salloum R, Franek BS, Kariuki SN, et al. Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patients. Arthritis Rheum. 2010;62:553-561.
36. Niewold TB, Kelly JA, Flesch MH, et al. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum. 2008;58:2481-2487.
37. Kariuki SN, Crow MK, Niewold TB. The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupus. Arthritis Rheum. 2008;58:2818-2823.
38. Dalmau J, Pimentel CL, Puig L, et al. Cutaneous necrosis after injection of polyethylene glycol-modified interferon alpha. J Am Acad Dermatol. 2005;53:62-66. (Pubitemid 40826695)
39. Schapira D, Nahir AM, Hadad N. Interferoninduced Raynaud's syndrome. Semin Arthritis Rheum. 2002;32:157-162.
40. Iorio R, Spagnuolo MI, Sepe A, et al. Severe Raynaud's phenomenon with chronic hepatitis C disease treated with interferon. Pediatr Infect Dis J. 2003;22:195-197. (Pubitemid 36228140)
41. Kruit WH, Eggermont AM, Stoter G. Interferonalpha induced Raynaud's syndrome. Ann Oncol. 2000;11:1501-1502.
42. Kaplan MJ. Premature vascular damage in systemic lupus erythematosus. Autoimmunity. 2009;42:580-586.
43. Andersson J, Libby P, Hansson GK. Adaptive immunity and atherosclerosis [published online ahead of print July 26, 2009]. Clin Immunol. 2010;134:33-46.
44. Niessner A, Shin MS, Pryshchep O, et al. Synergistic proinflammatory effects of the antiviral cytokine interferonalpha and toll-like receptor 4 ligands in the atherosclerotic plaque. Circulation. 2007;116:2043-2052. (Pubitemid 350023750)
45. Sugano S, Suzuki T, Watanabe M, et al. Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C. Am J Gastroenterol. 1998;93:2441-2444. (Pubitemid 29018552)
46. Zöhrens G, Armbrust T, Meyer Zum Büschenfelde KH, et al. Interferon-alpha 2a increases serum concentration of hyaluronic acid and type III procollagen aminoterminal propeptide in patients with chronic hepatitis B virus infection. Dig Dis Sci. 1994;39:2007-2013. (Pubitemid 2146976)
47. Myhr KM, Sadallah S, Mollnes TE, et al. Interferon-alpha2a effects on complement activation and regulation in MS patients. Acta Neurol Scand. 2000;101:30-35. (Pubitemid 30022043)
48. Kirou KA, Lee C, George S, et al. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005;52:1491-1503. (Pubitemid 40663941)
49. Magro CM, Crowson AN, Dawood M, et al. Parvoviral infection of endothelial cells and its possible role in vasculitis and autoimmune diseases. J Rheumatol. 2002;29:1227-1235. (Pubitemid 34601960)
50. Crowson AN, Magro CM, Dawood MR. A causal role for parvovirus B19 infection in adult dermatomyositis and other autoimmune syndromes. J Cutan Pathol. 2000;27:505-515.
51. Ferri C, Azzi A, Magro CM. Parvovirus B19 and systemic sclerosis [letter]. Br J Dermatol. 2005;152:819-820. (Pubitemid 40571332)
52. Liu SC, Tsai CT, Wu CK, et al. Human parvovirus b19 infection in patients with coronary atherosclerosis. Arch Med Res. 2009;40:612-617.
53. Bonvicini F, La Placa M, Manaresi E, et al. Parvovirus b19 DNA is commonly harboured in human skin. Dermatology. 2010;220:138-142.